secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001104659-25-050219
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata's AP-SA02 shows 100% clinical response in Phase 1b/2a S. aureus bacteremia trial
--------------------------------------------------------------------------------

- Primary endpoints met: safety, tolerability, and clinical response in ITT (n=50).
- AP-SA02 + BAT achieved 100% clinical response at TOC for BAT and EOS vs 75% for placebo (p=0.017).
- No treatment-related serious adverse events; two possibly related events (liver enzyme elevation, hypersensitivity).
- At day 12, responder rate 88% AP-SA02 vs 58% placebo (p=0.047); MRSA patients had no relapse.
- Company plans to initiate a pivotal trial as rapidly as possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465925050219/0001104659-25-050219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465925050219/tm2515395d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-050219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer